Shots:
- Relay to receive $75M as upfront, $25M in additional near-term payments, and has the right to opt for 50/50 profit/cost-sharing on RLY-1971 in the US. If Relay exercises the option, it will be eligible to receive 50% profits on US sales & ~$410M as commercialization milestones & royalties on ex-US sales
- If Relay elects not to opt-in, then it will receive ~$695M as milestones along with royalties on global sales of RLY-1971
- Genentech will assume the development of RLY-1971 with the potential to expand into multiple combination studies including its GDC-6036 (KRAS G12C inhibitor). The relay will receive additional royalties on the approval of IRLY-1971 + GDC-6036
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Fierce Biotech
The post Genentech Signs a Worldwide License Agreement with Relay Therapeutics to Develop and Commercialize RLY-1971 first appeared on PharmaShots.
